|
Velagluceraza alfa
Velagluceraza alfa (VPRIV) jeste hidrolitički lizozomalni glukocerebrozidno specifični enzim, koji je rekombinantna forma glukocerebrozidaze. Ovaj lek se koristi kao terapija dugotrajne enzimske zamene za obolele od Gaučerove bolesti tipa 1. On ima identičnu aminokiselinsku sekvencu sa prirodnim enzimom.[1] Odobren je za upotrebu u SAD februara 2010.[2][3][4][5][6]
Reference
- ^ University of Birmingham: Velaglucerase alfa for type 1 Gaucher’s disease Архивирано на сајту Wayback Machine (5. мај 2011)
- ^ Medical News Today: Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease Архивирано на сајту Wayback Machine (16. септембар 2020), 27 February 2010
- ^ Pastores GM: Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. PMID 20336596
- ^ Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, Michelin K, Ribeiro CB, Quevedo A, Vieira T, Nalin T, Lueska S, Schwartz IV: Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep. 2013 Feb 21. PMID 23430813
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
Literatura
Spoljašnje veze
|
|
